Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Urological Research Network Corp

Neither a doctor nor a teaching hospital

Research payments

$432,388

104 payments

Through program year 2025, Urological Research Network Corp is reported as receiving $432,388 in research payments, across 104 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $10,732 4
2024 Research $10,749 4
2023 Research $99,098 26
2022 Research $119,914 30
2021 Research $145,730 26
2020 Research $27,714 8
2019 Research $18,451 6

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $251,787 74 payments
  2. Clinical Laserthermia Systems Americas Inc. $145,100 7 payments
  3. Allergan Inc. $14,784 6 payments
  4. Idorsia Pharmaceuticals US Inc $11,682 4 payments
  5. Alnylam Pharmaceuticals Inc. $5,035 12 payments
  6. Ipsen Innovation $4,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Multinational Randomized Openlabel Three Parallelarm Study of Pf06801591 An Antipd1 Antibody in Combination With Bacillus Calmetteguerin BCG Induction With Or Without BCG Maintenance Versus BCG Induction and Maintenance in Participants With Highrisk Bcgnaive Nonmuscle Invasive Bladder Cancer $251,787 74 payments
  2. TRANBERG Transperineal MR/US Fusion Laser--Induced Thermal Therapy for Men With Prostate Cancer (TPF-LITT) $145,100 7 payments
  3. A Study Evaluating the Efficacy and Safety of BOTOX Intravesical Instillation in Patients with Overactive Bladder and Urinary Incontinence $14,451 5 payments
  4. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, 2-Way Cross-Over Post Approval Study to Investigate the Efficacy of Daridorexant in Subjects With Insomnia and Comorbid Nocturia $11,682 4 payments
  5. A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels $5,035 12 payments
  6. A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis $4,000 1 payment
  7. A Study Evaluating the Efficacy and Safety of BOTOX Intravesical Instillation in Patients with Overactive Bladder and Urinary Incontinence $333 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record